What the FDA's October 2026 Warning Letter to Olympus Says
Update, November 2, 2026: When this article was first published on October 28, it described a refusal of entry as something that might follow the warning letter. The FDA had already expanded an import alert covering certain Olympus devices on October 19 and 20, and we should have said so. See our explainer on the expanded import alert.
On October 13, 2026, Olympus Corporation announced that it had received a warning letter from the U.S. Food and Drug Administration dated October 7. The FDA posted the letter publicly on October 20. The letter is long and technical. This article sticks to its text and to Olympus’s own statements.
What a warning letter is, and is not
A warning letter is a formal notice from the FDA that an inspection found violations of federal rules. It gives the company 15 business days to respond in writing with the steps it has taken and a timetable for any fixes still under way. It is a regulatory document, not a court ruling, and the FDA notes that it is not an exhaustive list of every problem.
Where the FDA looked, and what it concluded
The letter follows inspections between October and November 2025 at six Olympus facilities: four in Japan (Hachioji, Hinode, Aomori and Shirakawa), one in Hamburg, Germany, and one in Brooklyn Park, Minnesota. The FDA also noted problems with complaint files at Olympus Corporation of the Americas in Pennsylvania.
The FDA said the facilities make a range of surgical and endotherapy devices, including hemostatic clips, sphincterotomes, cystoscopes, bronchoscopes, endoscope distal covers, valves and insufflators. It concluded that devices made at the six facilities are adulterated under federal law because the manufacturing methods and controls do not meet the Quality System regulation, which it said resulted in nonconforming devices being distributed and significant risks to patients.
The main categories of violations
The letter groups its findings under several headings. In plain terms:
- Design controls. The FDA said Olympus did not adequately validate some designs under realistic conditions. Examples include an insufflator whose risk documents did not reflect known catastrophic hazards, even after a patient death and a 2023 Class I recall, and bronchoscope instructions that claimed laser compatibility without validation testing.
- Nonconforming product and process validation. This includes sterile packaging seals that were not properly validated. For one plant, the FDA said seal wrinkles may create channels for microbial contamination, and it said one finding there repeats a violation from a 2023 warning letter.
- Corrective and preventive action. The FDA said recurring problems were not traced to root causes or fixed in ways that were verified to work.
- Suppliers and incoming inspection. The FDA cited weak controls over purchased components, including a supplier welding process that had not been validated.
- Complaints and adverse event reports. The FDA said some complaints were not investigated or trended properly and that some reports to the FDA were filed late.
Several findings involve devices used in endoscopy. For example, the FDA said Olympus received more than 1,000 complaints about deformed wires in a single-use sphincterotome (a cutting instrument passed through an endoscope), yet limited its manufacturing fix to products sold in Japan. In a separate finding on sphincterotomes, it said the company’s risk documents did not account for reports of unintended cutting of blood vessels leading to bleeding.
The parts that touch scope cleaning
Two findings relate to equipment used around scope reprocessing. One involves a design change to a water filter used in Olympus’s OER-Elite and OER-Mini endoscope reprocessors. The FDA said the verification testing was incomplete and the records did not show the filter lasts at least one month, as its requirements specify. The other says Olympus had not created design traceability matrices for several products, a list that includes the Evis Exera III duodenovideoscopes and the endoscope reprocessor.
What the letter does not say
Reading the full published text, we did not find any discussion of the contamination or infection problems with TJF-series duodenoscopes that are central to the injury lawsuits. The letter does not discuss patient infections from duodenoscope reprocessing, and it does not itself order a recall. For most findings, the FDA said it could not yet judge whether Olympus’s responses were adequate, because the corrective work is still ongoing.
The letter warns that failing to address the violations may lead the FDA to refuse entry of the company’s devices into the United States. As the update above notes, the FDA has since expanded an import alert covering certain devices made at three of the Japanese facilities.
What Olympus has said
In its October 13 announcement, Olympus said the letter primarily concerns its quality management system and related processes, and that it plans to respond within the 15-business-day deadline and send periodic updates afterward. Olympus also said the letter does not disrupt production and is not expected to affect its financial results. Its shares fell sharply after the news.
What happens next
The FDA will review Olympus’s response, tell the company whether it is adequate, and may re-inspect. The letter also notes that, after three earlier warning letters in 2022 and 2023, Olympus’s new global procedures still do not clearly divide responsibility between individual plants and its corporate quality organization.
How this relates to the lawsuits
Lawsuits over Olympus scope infections remain individual product liability cases, and no multidistrict litigation has been consolidated as of late October 2026. A warning letter does not decide any of those cases. Whether a regulatory document like this one matters in a particular case depends on its facts and on what a court allows, which is a question for a lawyer reviewing that case.
For background on the cleaning problem behind the earlier infection reports, see our explainer on why duodenoscopes are hard to clean. For the broader sequence of events, see the litigation timeline.
Sources
- FDA: Warning Letter to Olympus Medical Systems Corporation, CMS #729208 (October 7, 2026)
- Olympus: Olympus Receives FDA Warning Letter (October 13, 2026)
- MassDevice: Olympus receives FDA warning letter after international inspections (October 13, 2026)
- FDA: Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan, Letter to Health Care Providers (October 20, 2026)
- Bloomberg: Olympus Shares Slump on FDA Warning Letter on Six Facilities (October 14, 2026)
Facts in this article come from the sources listed above and were current when the article was published or last updated. Statements about lawsuits describe allegations, which are claims and not findings by a court.
This article is general information, not medical or legal advice. Reading it does not create an attorney-client relationship. If you have symptoms of an infection, contact your health care provider. Attorney advertising. Prior results do not guarantee a similar outcome.